Genedata Biologics Will Be Featured at 9th Annual Pharmaceutical IT Congress

Share Article

Biologics R&D advances with increasing industry adoption of first-in-class biologics data management platform

Genedata Biologics

Integrated tools for biologics R&D operations

Genedata Biologics meets the growing needs of biopharmas, which require support for standardizing and integrating specific and complex R&D processes.

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced it will showcase Genedata Biologics™ at the 9th Annual Pharmaceutical IT Congress. The software solution will be discussed as part of a Bayer HealthCare Pharmaceuticals presentation on the development of the Bayer integrated biologics data management platform. The Pharmaceutical IT Congress, an annual forum for R&D IT and pharmaceutical technologies, will be held at the Radisson Edwardian Hotel, London Heathrow (September 15 – 16).

The discovery and development of biopharmaceuticals is complex, time-consuming, and costly. It differs substantially from established small-molecule R&D processes. Consequently, the underlying laboratory and data management processes are unlike small molecule workflows and require a new dimension of IT support. Genedata and Bayer Healthcare will present findings from their four-year collaboration of developing and implementing a first-in-class turn-key solution for biologics R&D data management and exchange. The presentation will highlight:

  •     process complexity;
  •     adapting to innovative technologies and new processes;
  •     integration with existing IT infrastructure;
  •     scalability required to address increasing R&D project throughput;
  •     biologics molecule and sample registration;
  •     interfaces to external R&D partners and CROs; and
  •     quality control.

The Biologics R&D IT Platform
Genedata Biologics is the first commercially available biologics R&D IT platform. It is an open, scalable, and modular enterprise-level software solution, which enables more efficient and less error-prone biologics discovery and development processes.

Providing biologics R&D automation, standardization and integration, Genedata Biologics has a high degree of built-in business logic and is designed to adapt to corporate-specific processes and new discovery technologies. The product works out-of-the box in its default configuration, and can be implemented within days. As an enterprise system, it supports the concurrent usage of several hundred users. Genedata Biologics enables straight-forward integration with corporate compound registration systems and other R&D IT infrastructure such as project management tools and ELNs. The system scales with the ever growing data volumes in today’s biopharma discovery processes and can easily process and store millions of biologics molecules, vectors, cell lines, and other relevant entities.

The research community using Genedata Biologics includes: 1) established pharmaceutical companies in the process of building up internal biologics R&D operations to complement existing small-molecule R&D processes; 2) established biotech companies with significant in-house legacy software that requires life cycle replacements needed to address new requirements (e.g. next-generation antibody formats), or to overcome scalability bottlenecks; 3) small-and medium-sized biotechs and CROs requiring commercial software to support their growth path in terms of scope and scalability; and 4) generics companies that need software to support their growing biosimilar product portfolios.

“The successful market entry of our newest member of the Genedata product family shows that Genedata Biologics meets the growing needs of biopharmas, which require support for standardizing and integrating specific and complex R&D processes,” said Dr. Othmar Pfannes, CEO of Genedata. “In today’s biologics business, timing is key. The availability of a standard product drastically reduces implementation times for large-scale biopharma enterprise solutions. We will continue to invest in Genedata Biologics, which is facilitating the development of innovative bio-medicines.”

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery and life science research, which spans target, lead, and biomarker discovery. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata Phylosopher®, Genedata Screener®, Genedata Expressionist®, Genedata Analyst™, Genedata Selector™, and Genedata Biologics™ make research data accessible and understandable, enabling scientific discovery that fights disease and improves health worldwide. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Japan, Germany, and the US.

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Allison Kurz
+41 61 511 8459
Email >

Jackie Thrasivoulos
+1 508 881 3109
Email >
Visit website